OA12525A - Treatment of t cell disorders. - Google Patents

Treatment of t cell disorders. Download PDF

Info

Publication number: OA12525A
Authority: OA; OAPI
Prior art keywords: mice; cells; cell; thymus; castrated
Prior art date: 2000-10-13

Application number

OA1200300114A

Other languages

English (en)

Inventor

Richard Lennox Boyd

Original Assignee

Univ Monash

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-13

Filing date

2001-10-15

Publication date

2006-05-31

2001-10-15 Application filed by Univ Monash filed Critical Univ Monash

2006-05-31 Publication of OA12525A publication Critical patent/OA12525A/en

Links

208000037913 T-cell disorder Diseases 0.000 title claims abstract description 9
238000011282 treatment Methods 0.000 title claims description 37
210000001541 thymus gland Anatomy 0.000 claims abstract description 127
239000003163 gonadal steroid hormone Substances 0.000 claims abstract description 28
210000001185 bone marrow Anatomy 0.000 claims abstract description 18
230000011664 signaling Effects 0.000 claims abstract description 9
210000000130 stem cell Anatomy 0.000 claims abstract description 9
230000003394 haemopoietic effect Effects 0.000 claims abstract description 4
210000001744 T-lymphocyte Anatomy 0.000 claims description 102
238000004519 manufacturing process Methods 0.000 claims description 19
102000039446 nucleic acids Human genes 0.000 claims description 14
108020004707 nucleic acids Proteins 0.000 claims description 14
150000007523 nucleic acids Chemical class 0.000 claims description 14
108090000623 proteins and genes Proteins 0.000 claims description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 8
241000725303 Human immunodeficiency virus Species 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
108010000817 Leuprolide Proteins 0.000 claims description 7
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 7
229960004338 leuprorelin Drugs 0.000 claims description 7
230000003197 catalytic effect Effects 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
238000002347 injection Methods 0.000 claims description 6
230000009385 viral infection Effects 0.000 claims description 6
208000030507 AIDS Diseases 0.000 claims description 5
108700012941 GNRH1 Proteins 0.000 claims description 5
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
108090000994 Catalytic RNA Proteins 0.000 claims description 4
102000053642 Catalytic RNA Human genes 0.000 claims description 4
208000036142 Viral infection Diseases 0.000 claims description 4
238000012239 gene modification Methods 0.000 claims description 4
230000005017 genetic modification Effects 0.000 claims description 4
235000013617 genetically modified food Nutrition 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 4
108091092562 ribozyme Proteins 0.000 claims description 4
HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 3
108010037003 Buserelin Proteins 0.000 claims description 3
GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 3
108010069236 Goserelin Proteins 0.000 claims description 3
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
108010021717 Nafarelin Proteins 0.000 claims description 3
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 3
229960002719 buserelin Drugs 0.000 claims description 3
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 3
230000006378 damage Effects 0.000 claims description 3
108700025485 deslorelin Proteins 0.000 claims description 3
229960005408 deslorelin Drugs 0.000 claims description 3
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 3
238000009472 formulation Methods 0.000 claims description 3
229960002913 goserelin Drugs 0.000 claims description 3
108700020746 histrelin Proteins 0.000 claims description 3
HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims description 3
229960002193 histrelin Drugs 0.000 claims description 3
108700025096 meterelin Proteins 0.000 claims description 3
229960002333 nafarelin Drugs 0.000 claims description 3
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
229960004824 triptorelin Drugs 0.000 claims description 3
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 3
108010073521 Luteinizing Hormone Proteins 0.000 claims description 2
102000009151 Luteinizing Hormone Human genes 0.000 claims description 2
229940040129 luteinizing hormone Drugs 0.000 claims description 2
230000002459 sustained effect Effects 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
238000000034 method Methods 0.000 abstract description 18
241000699670 Mus sp. Species 0.000 description 198
210000004027 cell Anatomy 0.000 description 142
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 35
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 35
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 34
210000004443 dendritic cell Anatomy 0.000 description 34
210000001165 lymph node Anatomy 0.000 description 34
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 33
230000007423 decrease Effects 0.000 description 33
210000000981 epithelium Anatomy 0.000 description 25
230000003247 decreasing effect Effects 0.000 description 22
210000004185 liver Anatomy 0.000 description 19
210000000952 spleen Anatomy 0.000 description 17
238000004458 analytical method Methods 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 15
239000000427 antigen Substances 0.000 description 15
102000036639 antigens Human genes 0.000 description 15
108091007433 antigens Proteins 0.000 description 15
239000002243 precursor Substances 0.000 description 15
206010003694 Atrophy Diseases 0.000 description 14
230000000694 effects Effects 0.000 description 14
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 13
230000037444 atrophy Effects 0.000 description 13
230000001054 cortical effect Effects 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 13
229960004397 cyclophosphamide Drugs 0.000 description 12
230000002062 proliferating effect Effects 0.000 description 12
238000011161 development Methods 0.000 description 11
230000018109 developmental process Effects 0.000 description 11
230000002093 peripheral effect Effects 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 10
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 10
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 10
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 10
230000008859 change Effects 0.000 description 10
150000003431 steroids Chemical class 0.000 description 10
238000012360 testing method Methods 0.000 description 10
102100032912 CD44 antigen Human genes 0.000 description 9
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 9
230000007547 defect Effects 0.000 description 9
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
108091008874 T cell receptors Proteins 0.000 description 8
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
230000004044 response Effects 0.000 description 8
210000004989 spleen cell Anatomy 0.000 description 8
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
230000000692 anti-sense effect Effects 0.000 description 7
230000006870 function Effects 0.000 description 7
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000000987 immune system Anatomy 0.000 description 6
238000010166 immunofluorescence Methods 0.000 description 6
230000005012 migration Effects 0.000 description 6
238000013508 migration Methods 0.000 description 6
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
238000003318 immunodepletion Methods 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
238000010186 staining Methods 0.000 description 5
230000009471 action Effects 0.000 description 4
230000032683 aging Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
230000003292 diminished effect Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000001360 synchronised effect Effects 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
208000037357 HIV infectious disease Diseases 0.000 description 3
206010061598 Immunodeficiency Diseases 0.000 description 3
102000000704 Interleukin-7 Human genes 0.000 description 3
108010002586 Interleukin-7 Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
210000004544 dc2 Anatomy 0.000 description 3
230000002950 deficient Effects 0.000 description 3
210000003317 double-positive, alpha-beta immature T lymphocyte Anatomy 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
238000002372 labelling Methods 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
230000035800 maturation Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
210000000066 myeloid cell Anatomy 0.000 description 3
230000008569 process Effects 0.000 description 3
230000002294 pubertal effect Effects 0.000 description 3
230000004043 responsiveness Effects 0.000 description 3
230000003393 splenic effect Effects 0.000 description 3
210000002536 stromal cell Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000002992 thymic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
YGGIRYYNWQICCP-LDRBRYNMSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylamino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydrox Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 YGGIRYYNWQICCP-LDRBRYNMSA-N 0.000 description 2
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
206010003497 Asphyxia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108091027757 Deoxyribozyme Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010085012 Steroid Receptors Proteins 0.000 description 2
210000000662 T-lymphocyte subset Anatomy 0.000 description 2
210000000173 T-lymphoid precursor cell Anatomy 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
229950004398 broxuridine Drugs 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
230000011712 cell development Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
229940039412 ketalar Drugs 0.000 description 2
229960004184 ketamine hydrochloride Drugs 0.000 description 2
230000004807 localization Effects 0.000 description 2
229960003822 lutrelin Drugs 0.000 description 2
230000000873 masking effect Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
229940069575 rompun Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
102000005969 steroid hormone receptors Human genes 0.000 description 2
230000035882 stress Effects 0.000 description 2
238000007801 sublethal irradiation Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
238000012756 BrdU staining Methods 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
108010032795 CD8 receptor Proteins 0.000 description 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
102100025137 Early activation antigen CD69 Human genes 0.000 description 1
QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
208000037952 HSV-1 infection Diseases 0.000 description 1
108090001102 Hammerhead ribozyme Proteins 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 1
101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 description 1
101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
102100022297 Integrin alpha-X Human genes 0.000 description 1
102100038070 Interferon regulatory factor 7 Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102100033467 L-selectin Human genes 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
235000017284 Pometia pinnata Nutrition 0.000 description 1
240000007653 Pometia tomentosa Species 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000008901 benefit Effects 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
230000004992 fission Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
108090001052 hairpin ribozyme Proteins 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011368 intensive chemotherapy Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940100994 interleukin-7 Drugs 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000010445 mica Substances 0.000 description 1
229910052618 mica group Inorganic materials 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
210000000607 neurosecretory system Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000000123 paper Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000003716 rejuvenation Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000009168 stem cell therapy Methods 0.000 description 1
238000011476 stem cell transplantation Methods 0.000 description 1
238000009580 stem-cell therapy Methods 0.000 description 1
108010066312 streptavidin-tricolor Proteins 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012353 t test Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000005313 thymus development Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Oncology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA1200300114A 2000-10-13 2001-10-15 Treatment of t cell disorders. OA12525A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AUPR0745A AUPR074500A0 (en)	2000-10-13	2000-10-13	Treatment of t cell disorders

Publications (1)

Publication Number	Publication Date
OA12525A true OA12525A (en)	2006-05-31

Family

ID=3824803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300114A OA12525A (en)	2000-10-13	2001-10-15	Treatment of t cell disorders.

Country Status (15)

Country	Link
US (3)	US20030017153A1 (de)
EP (1)	EP1333845A4 (de)
JP (1)	JP2004509979A (de)
KR (1)	KR20030060912A (de)
CN (1)	CN1529607A (de)
AP (1)	AP2003002785A0 (de)
AU (2)	AUPR074500A0 (de)
BR (1)	BR0114595A (de)
CA (1)	CA2425815A1 (de)
EA (1)	EA005573B1 (de)
IL (1)	IL155433A0 (de)
NZ (1)	NZ525508A (de)
OA (1)	OA12525A (de)
WO (1)	WO2002030435A1 (de)
ZA (1)	ZA200302931B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040265285A1 (en) *	1999-04-15	2004-12-30	Monash University	Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040258672A1 (en) *	1999-04-15	2004-12-23	Monash University	Graft acceptance through manipulation of thymic regeneration
US20050020524A1 (en) *	1999-04-15	2005-01-27	Monash University	Hematopoietic stem cell gene therapy
US20070274946A1 (en) *	1999-04-15	2007-11-29	Norwood Immunoloty, Ltd.	Tolerance to Graft Prior to Thymic Reactivation
US20050042679A1 (en) *	1999-04-15	2005-02-24	Monash University	Diagnostic indicator of thymic function
US20060088512A1 (en) *	2001-10-15	2006-04-27	Monash University	Treatment of T cell disorders
US20080279812A1 (en) *	2003-12-05	2008-11-13	Norwood Immunology, Ltd.	Disease Prevention and Vaccination Prior to Thymic Reactivation
WO2006021955A2 (en) *	2004-08-23	2006-03-02	Mor Research Applications Ltd.	Use of bat monoclonal antibody for immunotherapy
WO2009033799A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
WO2009046877A2 (en) *	2007-09-11	2009-04-16	Mondobiotech Laboratories Ag	Use of a histrelin and leuprolide as therapeutic agents
US9580504B1 (en)	2013-11-07	2017-02-28	Curetech Ltd.	Pidilizumab monoclonal antibody therapy following stem cell transplantation
IL261713B2 (en) *	2016-03-19	2023-09-01	F1 Oncology Inc	Methods and preparations for the transfer of lymphocytes and their regulated expansion
AU2018209239B2 (en) *	2017-01-20	2023-02-02	ISR Immune System Regulation Holding AB (publ)	Novel compounds (immunorhelins- intracellular infections)
WO2018134370A1 (en)	2017-01-20	2018-07-26	Immune System Regulation Holding Ab	Novel compounds (immunorhelins)
WO2018134372A1 (en)	2017-01-20	2018-07-26	Immune System Regulation Holding Ab	Novel use of known compounds- intracellular infections
EP3585414A1 (de)	2017-02-22	2020-01-01	Immune System Regulation Holding AB	Gonadotropin-freisetzende hormone zur verwendung als adjuvans-immuntherapeutika

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2238700B1 (de) *	1973-07-24	1977-10-14	Takeda Chemical Industries Ltd
CS180644B2 (en) *	1973-09-29	1978-01-31	Takeda Chemical Industries Ltd	Process for preparing nonapeptides
JPS5726506B2 (de) *	1974-03-08	1982-06-04
US4005063A (en) *	1973-10-11	1977-01-25	Abbott Laboratories	[Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
DE2451841A1 (de) *	1973-11-01	1975-05-07	Wellcome Found	Biologisch aktive amide, verfahren zu ihrer herstellung und ihre verwendung
JPS50142563A (de) *	1974-04-26	1975-11-17
NL7505590A (nl) *	1974-05-18	1975-11-20	Hoechst Ag	Werkwijze voor het bereiden van peptiden met lh-rh/fsh-rh-werking.
AU497512B2 (en) *	1975-04-15	1978-12-14	Ici Australia Limited	Nona and deca-peptides
US4010125A (en) *	1975-06-12	1977-03-01	Schally Andrew Victor	[D-Trp6 ]-LH-RH and intermediates therefor
US4018726A (en) *	1975-06-12	1977-04-19	Andrew Victor Schally	[D-Phe6 ]-LH-RH and intermediates therefor
US4024121A (en) *	1976-01-27	1977-05-17	Schally Andrew Victor	(Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4049805A (en) *	1975-09-30	1977-09-20	Akzona Incorporated	Steroidal erythropoietic agents and therapeutic compositions and methods
DE2617646C2 (de) *	1976-04-22	1986-07-31	Hoechst Ag, 6230 Frankfurt	Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
GB1524747A (en) *	1976-05-11	1978-09-13	Ici Ltd	Polypeptide
US4089946A (en) *	1976-06-07	1978-05-16	American Home Products Corporation	Claudogenic-interceptive nonapeptides
US4218439A (en) *	1977-07-14	1980-08-19	The Salk Institute For Biological Studies	Peptide which inhibits gonadal function
DE2905502C2 (de) *	1979-02-14	1982-07-15	Hoechst Ag, 6000 Frankfurt	Verfahren zur Herstellung von LH-RH bzw. LH-RH-Analoga und Pyroglutamyl-N↑i↑m↑-dinitrophenyl-histidin
US4234571A (en) *	1979-06-11	1980-11-18	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4608251A (en) *	1984-11-09	1986-08-26	Pitman-Moore, Inc.	LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US5003011A (en) *	1985-04-09	1991-03-26	The Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
US4866160A (en) *	1985-04-09	1989-09-12	The Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
US5073624A (en) *	1985-04-09	1991-12-17	Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
US4656247A (en) *	1985-04-26	1987-04-07	Board Of Regents, The University Of Texas System	Effective hormonal peptides: D-3-QA1 6-LHRH
US4642332A (en) *	1985-04-26	1987-02-10	The Board Of Regents, The University Of Texas System	Effective hormonal peptides: D-3-Pal6 -LHRH
US4775361A (en) *	1986-04-10	1988-10-04	The General Hospital Corporation	Controlled removal of human stratum corneum by pulsed laser to enhance percutaneous transport
US4992421A (en) *	1988-04-19	1991-02-12	Abbott Laboratories	Luteinizing hormone releasing hormone antagonist
US5258492A (en) *	1988-10-21	1993-11-02	The Administrators Of The Tulane Educational Fund	LHRH analogues with cytotoxic moieties at the sixth position
US5399493A (en) *	1989-06-15	1995-03-21	The Regents Of The University Of Michigan	Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5144019A (en) *	1989-06-21	1992-09-01	City Of Hope	Ribozyme cleavage of HIV-I RNA
US5061620A (en) *	1990-03-30	1991-10-29	Systemix, Inc.	Human hematopoietic stem cell
US5410016A (en) *	1990-10-15	1995-04-25	Board Of Regents, The University Of Texas System	Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5434136A (en) *	1990-12-14	1995-07-18	Mathias; John R.	Treatment of motility disorders with a GNRH analog
US5199942A (en) *	1991-06-07	1993-04-06	Immunex Corporation	Method for improving autologous transplantation
CA2121370C (en) *	1991-11-22	2003-03-18	David H. Sachs	Specific tolerance in transplantation
US5624823A (en) *	1991-11-22	1997-04-29	The General Hospital Corporation	DNA encoding procine interleukin-10
WO1993013785A1 (en) *	1992-01-08	1993-07-22	The General Hospital Corporation	Induced tolerance to xenografts
US5658564A (en) *	1992-02-19	1997-08-19	The General Hospital Corporation	Xenograft thymus
US5876708A (en) *	1992-02-19	1999-03-02	The General Hospital Corporation	Allogeneic and xenogeneic transplantation
US6315772B1 (en) *	1993-09-24	2001-11-13	Transmedica International, Inc.	Laser assisted pharmaceutical delivery and fluid removal
US5643252A (en) *	1992-10-28	1997-07-01	Venisect, Inc.	Laser perforator
US5658892A (en) *	1993-01-15	1997-08-19	The General Hospital Corporation	Compound delivery using high-pressure impulse transients
US5614502A (en) *	1993-01-15	1997-03-25	The General Hospital Corporation	High-pressure impulse transient drug delivery for the treatment of proliferative diseases
US5759551A (en) *	1993-04-27	1998-06-02	United Biomedical, Inc.	Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
EP0702716A4 (de) *	1993-05-17	1999-05-26	Univ California	Gentherapy bei hiv-infektion und aids mit hilfe von ribozymen
AU685506B2 (en) *	1993-08-25	1998-01-22	Systemix, Inc.	Method for producing a highly enriched population of hematopoietic stem cells
JPH07166906A (ja) *	1993-12-14	1995-06-27	Nissan Motor Co Ltd	燃料カットと点火時期変更による加速スリップ制御装置
US5506207A (en) *	1994-03-18	1996-04-09	The Salk Institute For Biological Studies	GNRH antagonists XIII
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
GB9409985D0 (en) *	1994-05-18	1994-07-06	Medical Res Council	Vaccine against mycobacterial infections
US5814617A (en) *	1994-10-07	1998-09-29	The United States Of America As Represented By The Secretary Of The Navy	Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
US5736524A (en) *	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
ATE228000T1 (de) *	1995-07-21	2002-12-15	Us Gov Health & Human Serv	Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen
CA2227584A1 (en) *	1995-08-04	1997-02-20	The General Hospital Corporation	Transgenic swine and swine cells having human hla genes
AU6898996A (en) *	1995-08-21	1997-03-12	Cytrx Corporation	Compositions and methods for growth promotion
US5658822A (en) *	1996-03-29	1997-08-19	Vanguard International Semiconductor Corporation	Locos method with double polysilicon/silicon nitride spacer
US5741706A (en) *	1996-06-13	1998-04-21	Immusol, Incorporated	Anti-HIV ribozymes
WO1998023325A1 (en) *	1996-11-27	1998-06-04	The General Hospital Corporation	Compound delivery using impulse transients
US5985892A (en) *	1998-04-02	1999-11-16	Merck & Co., Ltd.	Antagonists of gonadotropin releasing hormone
US20040258672A1 (en) *	1999-04-15	2004-12-23	Monash University	Graft acceptance through manipulation of thymic regeneration
AUPP977899A0 (en) *	1999-04-15	1999-05-13	Monash University	Improvement of t cell mediated immunity
US20040018180A1 (en) *	1999-04-15	2004-01-29	Monash University	Stimulation of thymus for vaccination development
US20040013641A1 (en) *	1999-04-15	2004-01-22	Monash University	Disease prevention by reactivation of the thymus
US20040241842A1 (en) *	1999-04-15	2004-12-02	Monash University	Stimulation of thymus for vaccination development
US20050043245A1 (en) *	2003-08-11	2005-02-24	Siler -Khodr Theresa M.	Non-mammalian GnRH analogs and uses thereof in the immune system

2000
- 2000-10-13 AU AUPR0745A patent/AUPR074500A0/en not_active Abandoned
2001
- 2001-08-01 US US09/885,268 patent/US20030017153A1/en not_active Abandoned
- 2001-10-15 EA EA200300461A patent/EA005573B1/ru not_active IP Right Cessation
- 2001-10-15 AP APAP/P/2003/002785A patent/AP2003002785A0/en unknown
- 2001-10-15 WO PCT/AU2001/001291 patent/WO2002030435A1/en not_active Ceased
- 2001-10-15 NZ NZ525508A patent/NZ525508A/en unknown
- 2001-10-15 CN CNA018205143A patent/CN1529607A/zh active Pending
- 2001-10-15 IL IL15543301A patent/IL155433A0/xx unknown
- 2001-10-15 KR KR10-2003-7005234A patent/KR20030060912A/ko not_active Ceased
- 2001-10-15 AU AU9527001A patent/AU9527001A/xx active Pending
- 2001-10-15 US US10/399,213 patent/US20040132179A1/en not_active Abandoned
- 2001-10-15 JP JP2002533875A patent/JP2004509979A/ja active Pending
- 2001-10-15 OA OA1200300114A patent/OA12525A/en unknown
- 2001-10-15 CA CA002425815A patent/CA2425815A1/en not_active Abandoned
- 2001-10-15 EP EP01975859A patent/EP1333845A4/de not_active Withdrawn
- 2001-10-15 BR BR0114595-9A patent/BR0114595A/pt not_active IP Right Cessation
2003
- 2003-04-14 ZA ZA200302931A patent/ZA200302931B/en unknown
2006
- 2006-04-20 US US11/408,107 patent/US20060188521A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1333845A4 (de)	2006-05-31
AP2003002785A0 (en)	2003-06-30
EA005573B1 (ru)	2005-04-28
CA2425815A1 (en)	2002-04-18
WO2002030435A1 (en)	2002-04-18
AU9527001A (en)	2002-04-22
AUPR074500A0 (en)	2000-11-09
ZA200302931B (en)	2004-07-14
US20040132179A1 (en)	2004-07-08
CN1529607A (zh)	2004-09-15
EA200300461A1 (ru)	2003-10-30
JP2004509979A (ja)	2004-04-02
NZ525508A (en)	2004-10-29
US20060188521A1 (en)	2006-08-24
US20030017153A1 (en)	2003-01-23
IL155433A0 (en)	2003-11-23
KR20030060912A (ko)	2003-07-16
BR0114595A (pt)	2003-09-16
EP1333845A1 (de)	2003-08-13

Publication	Publication Date	Title
AU779067B2 (en)	2005-01-06	Improvement of T cell mediated immunity
OA12525A (en)	2006-05-31	Treatment of t cell disorders.
US20040258672A1 (en)	2004-12-23	Graft acceptance through manipulation of thymic regeneration
US20040259803A1 (en)	2004-12-23	Disease prevention by reactivation of the thymus
CA2462681A1 (en)	2002-04-18	Disease prevention by reactivation of the thymus
AU2001295270C1 (en)	2002-04-22	Treatment of T cell disorders
US20060229251A1 (en)	2006-10-12	Treatment of T cell disorders
US20050042679A1 (en)	2005-02-24	Diagnostic indicator of thymic function
US20040265285A1 (en)	2004-12-30	Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AU2001295270A1 (en)	2002-06-27	Treatment of T cell disorders
CA2462046A1 (en)	2002-04-18	Improvement of graft acceptance through manipulation of thymic regeneration
AU2002216323B2 (en)	2007-11-15	Disease prevention by reactivation of the thymus
US20070274946A1 (en)	2007-11-29	Tolerance to Graft Prior to Thymic Reactivation
US20040037816A1 (en)	2004-02-26	Graft acceptance through manipulation of thymic regeneration
US20040037817A1 (en)	2004-02-26	Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20020110540A1 (en)	2002-08-15	Disease prevention by reactivation of the thymus
AU2002216323A1 (en)	2002-06-27	Disease prevention by reactivation of the thymus
ZA200303684B (en)	2005-05-25	Stimulation of thymus for vaccination development
ZA200303686B (en)	2004-10-13	Disease prevention by reactivation of the thymus.